Compare FUNC & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | CRBU |
|---|---|---|
| Founded | 1900 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.8M | 192.4M |
| IPO Year | 2012 | 2021 |
| Metric | FUNC | CRBU |
|---|---|---|
| Price | $37.15 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 7.7K | ★ 1.5M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 19.68 | 3.64 |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $18,426,000.00 | N/A |
| Revenue This Year | $13.05 | $1.63 |
| Revenue Next Year | $6.56 | $10.93 |
| P/E Ratio | $35.97 | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $28.00 | $0.96 |
| 52 Week High | $41.95 | $3.53 |
| Indicator | FUNC | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 46.32 |
| Support Level | $36.43 | $1.71 |
| Resistance Level | $37.68 | $2.06 |
| Average True Range (ATR) | 0.72 | 0.15 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 26.78 | 28.16 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.